Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients
with metastatic breast cancer after failing other treatments. Cetuximab is active against
tumors expressing epidermal growth factor receptor w/demonstrated activity in head & neck and
colorectal tumors and may be effective in some breast cancers known to express EGFR. Study
seeks to evaluate Ixabepilone alone or in combination with cetuximab as a an antitumor
therapy w/randomization stratified by stage (T1N1-3M0 or T2-4 N0-3M0).
Phase:
Phase 2
Details
Lead Sponsor:
Jenny C. Chang, MD The Methodist Hospital Research Institute
Collaborators:
Bristol-Myers Squibb The Methodist Hospital System